Comparison of risk scores for predicting outcomes after isolated tricuspid valve surgery
- PMID: 34672020
- DOI: 10.1111/jocs.16098
Comparison of risk scores for predicting outcomes after isolated tricuspid valve surgery
Abstract
Background: Risk models play important roles in stratification and decision-making towards cardiac surgery. Isolated tricuspid valve surgery is a high risk but increasingly performed the operation, however, the performance of risk models has not been externally evaluated in these patients. We compared the prognostic utility of contemporary risk scores for isolated tricuspid valve surgery.
Methods: Consecutive patients undergoing isolated tricuspid valve surgery at Cleveland Clinic during 2004-2018 were evaluated in this cohort study. EuroSCORE II, Society of Thoracic Surgeon's tricuspid (STS-TVS) score, and the Model for End-stage Liver Disease (MELD) score were retrospectively calculated, and their performance for predicting operative mortality, postoperative complications, and mortality during follow-up was assessed.
Results: Amongst 207 patients studied, the mean age was 54.1 ± 17.9 years, 116 (56.0%) were female, 92 (44.4%) had secondary tricuspid regurgitation, and 151 (72.9%) had a surgical repair. Mean EuroSCORE II, STS-TVS, and MELD scores were 6.3 ± 6.6%, 5.5 ± 6.2%, and 9.8 ± 4.7, respectively. C-statistics (95% confidence intervals) for operative mortality were 0.83 (0.74-0.93) for EuroSCORE II, 0.60 (0.45-0.75) for STS-TVS score, and 0.74 (0.58-0.89) for MELD score, while observed/expected ratios were 0.78 and 0.89 for the first two scores. All three scores were associated with mortality during follow-up and discriminated most postoperative complications.
Conclusion: EuroSCORE II was superior to STS-tricuspid score for isolated TVS risk assessment. Although surgical risk scores traditionally underestimated operative mortality after isolated tricuspid valve surgery, they did not in our cohort, reflecting the excellent surgical results. The simple MELD score performed similarly to the EuroSCORE II, especially for discriminating morbidities.
Keywords: risk score; tricuspid regurgitation; tricuspid valve; valve surgery.
© 2021 Wiley Periodicals LLC.
Similar articles
-
Risk stratification for isolated tricuspid valve surgery assisted using the Model for End-Stage Liver Disease score.J Thorac Cardiovasc Surg. 2023 Nov;166(5):1433-1441.e1. doi: 10.1016/j.jtcvs.2021.11.102. Epub 2022 Mar 12. J Thorac Cardiovasc Surg. 2023. PMID: 35431033
-
Comparison of Risk Scores for Prediction of Complications following Aortic Valve Replacement.Heart Lung Circ. 2015 Jun;24(6):595-601. doi: 10.1016/j.hlc.2014.11.021. Epub 2014 Dec 12. Heart Lung Circ. 2015. PMID: 25616680
-
Prediction of mortality in isolated tricuspid surgery.J Card Surg. 2022 Jan;37(1):135-137. doi: 10.1111/jocs.16104. Epub 2021 Oct 21. J Card Surg. 2022. PMID: 34674305
-
Isolated surgical tricuspid repair versus replacement: meta-analysis of 15 069 patients.Open Heart. 2020 Mar 17;7(1):e001227. doi: 10.1136/openhrt-2019-001227. eCollection 2020. Open Heart. 2020. PMID: 32206317 Free PMC article.
-
Risk stratification for surgery in tricuspid regurgitation.Prog Cardiovasc Dis. 2019 Nov-Dec;62(6):500-504. doi: 10.1016/j.pcad.2019.11.015. Epub 2019 Dec 5. Prog Cardiovasc Dis. 2019. PMID: 31812512 Review.
Cited by
-
Identification of risk factors for infection after mitral valve surgery through machine learning approaches.Front Cardiovasc Med. 2023 Jun 13;10:1050698. doi: 10.3389/fcvm.2023.1050698. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37383697 Free PMC article.
-
Deviations From the Ideal Plasma Volume and Isolated Tricuspid Valve Surgery-Paving the Way for New Risk Stratification Parameters.Front Cardiovasc Med. 2022 Mar 25;9:849972. doi: 10.3389/fcvm.2022.849972. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35402525 Free PMC article.
-
Prognostic Value of Modified Model for End-Stage Liver Disease Score in Patients Undergoing Isolated Tricuspid Valve Replacement.Front Cardiovasc Med. 2022 Jul 1;9:932142. doi: 10.3389/fcvm.2022.932142. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35845070 Free PMC article.
-
Tricuspid Valve Regurgitation: Current Understanding and Novel Treatment Options.J Soc Cardiovasc Angiogr Interv. 2023 Jul 5;2(5):101041. doi: 10.1016/j.jscai.2023.101041. eCollection 2023 Sep-Oct. J Soc Cardiovasc Angiogr Interv. 2023. PMID: 39132395 Free PMC article. Review.
-
New therapeutic approach for tricuspid regurgitation: Transcatheter tricuspid valve replacement or repair.Front Cardiovasc Med. 2023 Feb 23;10:1080101. doi: 10.3389/fcvm.2023.1080101. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36910541 Free PMC article. Review.
References
REFERENCES
-
- Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-2791.
-
- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;77(4):e25-e197.
-
- Kundi H, Popma JJ, Cohen DJ, et al. Prevalence and outcomes of isolated tricuspid valve surgery among medicare beneficiaries. Am J Cardiol. 2019;123(1):132-138.
-
- Vassileva CM, Shabosky J, Boley T, Markwell S, Hazelrigg S. Tricuspid valve surgery: the past 10 years from the Nationwide Inpatient Sample (NIS) database. J Thorac Cardiovasc Surg. 2012;143(5):1043-1049.
-
- Zack CJ, Fender EA, Chandrashekar P, et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol. 2017;70(24):2953-2960.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical